Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) (SMFG) Price & Performance

Merck & Co., Inc.Trade
Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)Trade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) — how do they compare? Merck & Co., Inc. trades at $142.17 (market cap $351.28B), while Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $24.84 (market cap $156.97B). The key difference: Merck & Co., Inc. is far larger — about 2.2× Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)'s market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 0 Days on average.

MRKSMFG
Market Cap
$351.28B$156.97B
Volume
7,969,6651,237,125
Sector
HealthFinancials
52-Week High
$156.43$27.56
52-Week Low
$82.49$15.20
Typical Hold Time
98 Days0 Days
Enterprise Value
$398.04B$12.48T
Dividend Yield
2.39%2.34%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.

The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.

Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MRK
18% Buy82% Sell
Avg holding period · 98 Days
SMFG
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK →

About Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)

Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.

Read more on SMFG →